Back to Results
First PageMeta Content
Vaccines / Acetamides / Neuraminidase inhibitors / Pandemics / Oseltamivir / FluMist / Influenza pandemic / Influenza treatment / Medicine / Influenza / Health


26 March 2015 EMACommittee for Medicinal Products for Human Use (CHMP) Summary of opinion 1 (post authorisation)
Add to Reading List

Document Date: 2015-03-27 08:06:58

Open Document

File Size: 72,80 KB

Share Result on Facebook

City

London / /

Company

Roche Registration Ltd. / /

Country

United Kingdom / /

Facility

Canary Wharf / /

IndustryTerm

medicinal product / /

MedicalCondition

influenza viruses / disease / pandemic influenza / clinically diagnosed influenza / influenza virus / predominant infection / influenza A / naturally occurring influenza / influenza / /

MedicalTreatment

vaccination / /

Organization

Committee for Medicinal Products for Human Use / European Union / European Medicines Agency / contact An / European Commission / /

/

Position

treating physician / /

Product

Tamiflu / /

URL

www.ema.europa.eu/contact / /

SocialTag